# Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

> **NCT03503864** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yang Li** · enrollment: 80 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Arsenic Trioxide

## Key facts

- **NCT ID:** NCT03503864
- **Lead sponsor:** Yang Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-12
- **Primary completion:** 2023-08-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03503864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03503864, "Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03503864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*